ERAS

ERAS is exhibiting a classic 'Institutional Absorption' breakout, decoupling from the macro 'Caution' regime driven by a successful strategic pivot to its Pan-RAS molecular glue franchise (ERAS-0015). The stock has digested a massive $258M upsized equity offering priced at $10.00 (Jan 23, 2026), using the capital to fully fund its new high-conviction pipeline. While the broad market struggles with 'AI anxiety,' smart money is rotating into this de-risked biotech story, validated by the stock holding firm above the offering price and pushing new highs.